Cirrus Therapeutics, an ocular immunology-focused biotech, announced today the close of an $11 million seed financing to advance its pipeline of gene and cell therapies aimed at improving quality of life and extending the ocular healthspan of patients with chronic blinding diseases. The round was led by ClavystBio, with participation from Polaris Partners and SEEDS.
Cirrus Therapeutics has raised an $11 million seed round toward its bet that altering the immune function of the eye using gene therapy can slow or potentially stop aging-related conditions that rob people of their sight.
Uveitis is characterized by inflammation of the uvea and primarily affects adults aged 20 to 50 years. For noninfectious anterior uveitis, corticosteroid eyedrops are first-line treatment. For posterior noninfectious uveitis, disease-modifying antirheumatic drugs are first-line therapy; biologics su …
The Foundation Fighting Blindness and the Retinal Degeneration Fund (RD Fund) hosted their annual Investing in Cures Summit (ICS) on March 21 and 22, 2025 in Tampa to highlight the strong progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.